FutureCure Health completes Rs 104 crore funding round for vertigo care expansion

FutureCure Health has completed a Rs 104 crore funding round to expand access to the diagnosis and treatment of vertigo and balance disorders. Vertigo and balance disorders impact nearly six crore people in India, with many patients being misdiagnosed or treated using symptom-suppressing medication rather than therapy directed at the underlying condition.

The investment round was led by Carnelian Asset Management LLP, with participation from other investors. The fundraising follows an earlier USD 4 million round completed in 2022, which was backed by Kotak Alternate Asset Management, RVCF Ventures, and Unicorn India Ventures.

FutureCure Health operates NeuroEquilibrium, its wholly owned subsidiary, which runs a network of vertigo and dizziness diagnostic and rehabilitation clinics with the highest number of such centres globally. NeuroEquilibrium follows a diagnostic approach focused on identifying the source of vertigo, whether linked to the inner ear, the brain, or balance pathways, with treatment directed at the identified cause. The clinics work with hospitals, ENT clinics, and neurology centres.

NeuroEquilibrium operates more than 300 clinics across India and 16 other countries. Through this network, the company has enabled diagnosis and treatment for over 150,000 patients.

Rajneesh Bhandari, Founder, FutureCure Health, said, “This funding has reinforced our conviction that globally relevant healthcare technologies can be built in India. As we scale NeuroEquilibrium across hospitals in India and globally and expand into chronic lifestyle diseases such as migraine and diabetes, our focus is on using technology to bridge the shortage of specialist doctors. Precise, scalable diagnostics can democratise super-speciality healthcare and act as a true force multiplier for better outcomes.”

Dr Anita Bhandari, Founder, FutureCure Health, said, “Vertigo/dizziness is often misdiagnosed, leaving patients untreated for years. Our work with 150,000+ patients proves that accurate diagnosis changes outcomes. This funding will help us take specialised vertigo care global.”